Table 2.
Clinical characteristics of MPN according to the occurrence of infectious events.
| Characteristics | Total | No Infection | Infection | p |
|---|---|---|---|---|
| Age | ||||
| >65 years—no. (%) | 483 (51.0) | 287 (59.4) | 196 (40.6) | 0.01 |
| MPN subtype | ||||
| PV—no. (%) | 287 (30.3) | 144 (50.2) | 143 (49.8) | 0.75 |
| ET—no. (%) | 388 (40.9) | 204 (52.6) | 184 (47.4) | 0.11 |
| MF—no. (%) | 223 (23.5) | 95 (42.6) | 128 (57.4) | 0.022 |
| MPN-U—no. (%) | 24 (2.5) | 12 (50.0) | 12 (50.0) | 0.93 |
| CML—no. (%) | 26 (2.8) | 13 (50.0) | 13 (50.0) | 0.92 |
| Driver mutation | ||||
| JAK2—no. (%) | 682 (78.3) | 342 (50.1) | 340 (49.9) | 0.45 |
| MPL—no. (%) | 26 (3.0) | 13 (50.0) | 13 (50.0) | 0.93 |
| CALR—no. (%) | 131 (15.0) | 62 (47.3) | 67 (52.7) | 0.64 |
| Triple negative—no. (%) | 32 (3.7) | 13 (40.6) | 19 (59.4) | 0.32 |
| Therapy | ||||
| No medication—no. (%) | 171 (18.0) | 76 (44.4) | 95 (55.6) | 0.12 |
| HU—no. (%) | 407 (42.9) | 257 (63.1) | 150 (36.9) | 0.01 |
| Ruxolitinib—no. (%) | 170 (17.9) | 54 (31.8) | 116 (68.2) | 0.01 |
| Combination—no. (%) | 53 (5.6) | 16 (30.2) | 37 (69.8) | 0.04 |
| Interferon—no. (%) | 57 (6.0) | 22 (38.6) | 35 (61.4) | 0.09 |
| Other—no. (%) | 90 (9.5) | 44 (48.9) | 46 (51.1) | 0.94 |
Combination therapies included RUX plus either agent: hydroxyurea, pomalidomide, MDM2-inhibitors, BET-inhibitors, or interferon alpha.
no. number, PV polycythemia vera, ET essential thrombocythemia, MF myelofibrosis, MPN-U MPN unclassifiable, HU hydroxyurea.